EUVIMEDOpdag EUVIMED
Übersichtsarbeit

The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities

Nila Ganamurali, Sarvesh Sabarathinam

Clinical Pharmacology in Drug Development · 2026

DOI: 10.1002/cpdd.70001 ↗

At a glance

Übersichtsarbeit in Clinical Pharmacology in Drug Development, 2026. Written by Nila Ganamurali and 1 co-authors. Institution: Helix Research Lab, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chenna…. Major MEDLINE topics: Obesity, Glucagon-Like Peptide-1 Receptor Agonists, Anti-Obesity Agents, Receptors, Gastrointestinal Hormone. Cited 9 times so far (Crossref); 49 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Obesity has emerged as a global health crisis requiring innovative therapeutic strategies beyond conventional approaches. While glucagon‐like peptide‐1 (GLP‐1) and dual GIP/GLP‐1 receptor agonists have redefined pharmacological management, their limitations necessitate further innovation. Retatrutide (LY3437943), a novel triple agonist targeting GLP‐1, glucose‐dependent insulinotropic polypeptide (GIP), and glucagon receptors, represents a transformative advance in obesity pharmacotherapy. Phase 2 trials report unprecedented weight reductions, comparable to bariatric surgery, with additional benefits for metabolic comorbidities such as NASH and cardiovascular disease. Retatrutide exemplifies rational multi‐agonist peptide engineering and signals a paradigm shift in systems pharmacology. This perspective underscores the urgent need for scientific engagement, equity considerations, and policy preparedness, positioning retatrutide as a watershed in obesity treatment and a blueprint for future poly‐agonist therapies.

Subjects

MeSH terms (MEDLINE)

ObesityGlucagon-Like Peptide-1 Receptor AgonistsAnti-Obesity AgentsReceptors, Gastrointestinal HormoneCardiovascular DiseasesHumansAnimalsReceptors, GlucagonGastric Inhibitory PolypeptideComorbidityFatty AcidsPeptides

Author keywords

GLP‐1/GIP/glucagon receptorequitable access to obesity careinnovation in therapeutic technologiesmetabolic health advancementobesity pharmacotherapyretatrutidesystems pharmacologytriple agonist therapy

Substances

Glucagon-Like Peptide-1 Receptor AgonistsAnti-Obesity AgentsReceptors, Gastrointestinal Hormonegastric inhibitory polypeptide receptorReceptors, GlucagonGastric Inhibitory PolypeptideretatrutideFatty AcidsPeptides

Authors and institutions

  • Helix Research Lab, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, Tamil Nadu, India.

Cite

APA

Ganamurali, N., & Sabarathinam, S. (2026). The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70001

Vancouver

Ganamurali N, Sabarathinam S. The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.70001

BibTeX
@article{Ganamurali2026,
  author = {Ganamurali, Nila and Sabarathinam, Sarvesh},
  title = {The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  doi = {10.1002/cpdd.70001}
}
Start for free →